Department of Health and Human Services
Part 1. Overview Information

 

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative (https://commonfund.nih.gov/) through the NIH Office of the NIH Director, Office of Strategic Coordination (https://commonfund.nih.gov/). All NIH Institutes and Centers participate in Common Fund initiatives. This FOA will be administered by the National Institute on Drug Abuse (NIDA).

Funding Opportunity Title

Omics Data Generation Centers (ODGCs) for Common Fund Acute to Chronic Pain Signatures Program (U54 Clinical Trial Optional)

Activity Code

U54 Specialized Center- Cooperative Agreements

Announcement Type

New

Related Notices
Funding Opportunity Announcement (FOA) Number

RFA-RM-18-032

Companion Funding Opportunity

RFA-RM-18-031 U54 Specialized Center--Cooperative Agreements

RFA-RM-18-033 UM1 Research Project with Complex Structure Cooperative Agreement

RFA-RM-18-034 UM1 Research Project with Complex Structure Cooperative Agreement

RFA-RM-18-035 U24 Resource-Related Research Projects--Cooperative Agreements

Catalog of Federal Domestic Assistance (CFDA) Number(s)

 93.310 

Funding Opportunity Purpose

The purpose of this FOA is to support the establishment of center(s) that will use cutting edge technologies to perform omics analyses (e.g. metabolomic, lipidomic, proteomic, extracellular RNA) of body fluids collected by the Acute to Chronic Pain Signatures (A2CPS) consortium. The omics data generated, in concert with other patient assessments, will be used to identify biosignatures predictive of susceptibility or resilience to the development of chronic pain.   

Key Dates

 

Posted Date

August 24, 2018

Open Date (Earliest Submission Date)

September 24, 2018

Letter of Intent Due Date(s)

September 24, 2018

Application Due Date(s)

October 24, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

AIDS Application Due Date(s)

Not applicable

Scientific Merit Review

February 2019

Advisory Council Review

May 2019

Earliest Start Date

June 1, 2019

Expiration Date

October 25, 2018

Due Dates for E.O. 12372

Not Applicable

** ELECTRONIC APPLICATION SUBMISSION REQUIRED**

NIH’s new Application Submission System & Interface for Submission Tracking (ASSIST) is available for the electronic preparation and submission of multi-project applications through Grants.gov to NIH. Applications to this FOA must be submitted electronically using ASSIST or an institutional system-to-system solution; paper applications will not be accepted.

Required Application Instructions

It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.


There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.

  3. Table of Contents

    Part 1. Overview Information
    Part 2. Full Text of the Announcement

    Section I. Funding Opportunity Description
    Section II. Award Information
    Section III. Eligibility Information
    Section IV. Application and Submission Information
    Section V. Application Review Information
    Section VI. Award Administration Information
    Section VII. Agency Contacts
    Section VIII. Other Information


    Part 2. Full Text of Announcement
    Section I. Funding Opportunity Description

    BACKGROUND:

    The United States faces a crisis due to the high prevalence of chronic pain and associated opioid use disorder and overdose deaths. More than 25 million adults in the U.S. report experiencing pain every day. A major challenge in pain care is the lack of evidence-based best practices to prevent chronic pain from occurring after an acute pain episode. For most people, acute pain resolves over time as the injury or trauma heals. In many people however, acute pain from injury, surgery, or disease processes persists well beyond the initial insult (sometimes throughout life) and is often intractable. Chronic pain persists beyond recovery due to changes in the peripheral and central nervous systems. However, the mechanisms driving acute pain transition to a chronic state are poorly understood.

    The ability to predict which patients are more likely to be susceptible versus resilient to the development of chronic pain is a crucial step towards the development of personalized prevention strategies to transform acute pain treatment approaches and reduce or prevent chronic pain. Toward this end, the NIH Common Fund supported Acute to Chronic Pain Signatures (A2CPS) Program aims to identify biosignatures (a combination of several individual biomarkers) that predict susceptibility or resilience to the development of chronic pain after an acute pain event. Furthermore, if any of the predictive biomarkers identified through this program play a mechanistic role in the development of chronic pain, then the molecules, pathways, and/or brain circuits identified could serve as new potential therapeutic targets for reversing chronic pain or increasing patient resilience to chronic pain.

    A2CPS is part of the multi-pronged HEAL (Helping to End Addiction Long-term) Initiative, an aggressive effort to speed scientific solutions to stem the national opioid public health crisis (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative). HEAL will build on extensive, well-established NIH research to address the opioid crisis and provide safer therapies for people with pain. Funding for A2CPS will be from the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact. All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress.

    Overall A2CPS Program Description: The A2CPS program will be funded as cooperative agreements through five linked FOAs. Awardees will work together as a consortium with strong communication and cooperation. The A2CPS program will support two longitudinal prospective studies on large cohorts of patients who experience acute pain from either a specific surgical procedure or a specific musculoskeletal trauma. The goal of the program is to identify candidate biomarkers and combine them into biosignatures predictive of the susceptibility or resilience to the development of chronic pain. The candidate biomarkers to be tested as primary outcomes in the two studies will be selected by a panel of external experts, consortium awardees, and NIH staff, who will consider the most promising biomarkers of transition or resilience to chronic pain based on current evidence. The size of each cohort is expected to be approximately 1800 patients, and the number of study biomarkers identified as primary study outcomes is expected to be approximately 40, based on an NIH power analysis calculation.

    Overall, the A2CPS program will:

    • establish a Clinical Coordinating Center (CCC) (RFA-RM-18-035) to support study design, efficiency, and quality; develop protocols and contracts; train clinical staff in study procedures; and develop, coordinate, and monitor study implementation at the consortium’s clinical sites. The CCC will lead the development of the clinical protocols in the planning year.
    • support two Multisite Clinical Centers (MCCs) (RFA-RM-18-033 and RFA-RM-18-034), each of which will recruit one of the homogeneous pain cohorts at onset of an acute pain event; deliver, monitor, and record usual pain care including opioid and other analgesic use; assess patients for study-determined characteristics including detailed patient reported outcomes (historical data such as previous surgeries, trauma, substance abuse, concurrent pain conditions, depression, somatization tendencies, support system, etc); perform brain imaging, sensory tests, and collect biospecimens at onset of acute pain and follow-up (time = 0, 3 months, and 6 months).
    • support one or more Omics Data Generation Centers (ODGCs) (RFA-RM-18-032) with expertise and resources to generate a diverse set of omics data from the biospecimens collected.  Biospecimens will be analyzed extensively by the ODGCs using high-throughput technologies that allow rapid identification of many different biological molecules from large numbers of samples. Because the majority of the potential circulating/tissue biomarkers in the literature at this time are from 4 categories: proteomics, lipidomics, metabolomics, and extracellular RNA, it is expected the ODGCs will have expertise in these areas. Applicants to this component will be required to set aside 20% of their budget in order to add in any compelling additional omics assays identified during the planning year.
    • collect patient biospecimens sufficient for ODGC analysis. The ODGC will set aside 20% of the budget to have the flexibility to add assays as determined in the planning year. If added funds become available, collection of additional biospecimens for future analysis by novel or dramatically improved assays may also be considered during the planning year.  There will be a transparent and rigorous biospecimen reporting structure in place as well as a process whereby PIs across the consortium can access biospecimens to perform tests. At the end of the study, all unused biospecimens will be submitted to an appropriate NIH repository.
    • establish a Data Integration Resource Center (DIRC) (RFA-RM-18-031) to receive data from the CCC, MCCs, and ODGCs for coordination, standardization, collection, integration, and statistical analysis of the clinical, imaging, and omics data. The DIRC will make the A2CPS data available to the scientific community using resources obtained through the NIH Data Commons (https://commonfund.nih.gov/commons) to ensure the data will be FAIR (Findable, Accessible, Interoperable, and Reusable) and accessible via cloud based data storage and computing. The DIRC also will develop a virtual biospecimen repository, build a publicly accessible database/website, coordinate logistics, such as organizing PI meetings, and perform outreach activities. 
    • be governed by a Steering Committee of A2CPS investigators and NIH staff that will oversee development of consensus policies, protocols, and procedures for consortium-wide activities such as clinical coordination, data collection, and resource sharing. 
    • receive input on development and progress of the project from a panel of External Program Consultants (EPCs), a group of experts with broad, relevant expertise, who are independent of the awards.

    Timeline:  The first year of the program (estimated to be summer 2019-summer 2020) will be a planning year during which limited funds will be awarded to awardees for all five FOAs. In this year, the EPCs and Steering Committee will be established, the consortium will develop the clinical protocols, standard operating procedures, staff training plans, recruitment plans, electronic health record standardization, safety standards and regulatory processes, identify biospecimen types and amounts to be collected, and develop biospecimen collection and storage protocols. The consortium will assess and refine the statistical analysis plan (including power analysis) for each cohort. At the kick-off meeting or shortly thereafter, an expert panel, including consortium members, the EPCs, and outside experts will select approximately 40 evidence-based high value candidate biomarkers for primary study outcomes.

    The planning year will be followed by up to three additional years (duration varies across awards) of higher funding levels, during which the study will be implemented. We anticipate patient enrollment to begin in summer 2020, immediately after the planning year. In July 2021 or at approximately 50% completion of 6 month phenotyping, a futility assessment will be performed to determine whether the rate of transition to chronic pain and patient retention is adequate to meet the assumptions of the power analysis. In the event of lower than expected transition or poor retention of patients, the A2CPS Steering Committee with the EPCs will make recommendations to NIH to either increase enrollment or terminate the study. NIH leadership will make the final determination. We expect enrollment to be complete by July 2022, and clinical assessments to be complete by January 2023. Data analysis and public archiving of the data for data mining efforts by the scientific community should be complete by February 2024. 

    ODGC Scope.  Although a final set of patient assessments has not yet been established, it is anticipated that there will be two cohorts of approximately 1800 patients each (3600 patients total). Biospecimens, most likely blood, but possibly urine or other specimens, will be collected from these patients at the t=0, 3, and 6 month time points by the MCCs.  t=0 will be at or before the time of an acute pain event. Patients will be assessed for chronic pain at t=6 months. The consortium will establish the amount and method of sample collection and storage during the planning year. Thus, there will be approximately 11,000 samples to be molecularly characterized, not counting any replicates that might be needed.

    NIH anticipates funding 1-3 ODGCs with expertise in biomarker profiling assays. Because the majority of the potential circulating/tissue biomarkers in the literature at this time are from 4 categories: proteomics, lipidomics, metabolomics, and extracellular RNA, it is expected that applicants to this FOA will have expertise in these areas. These Centers will be expected to provide resources and expertise to perform high quality and reproducible assays on the consortium selected high value candidate biomarkers and additional secondary biomarkers. ODGCs will be required to set aside 20% of their budget in order to add in any compelling additional omics assays identified during the planning year.

    U54 mechanism.  Awards made under this FOA will utilize the U54 specialized center mechanism. A cooperative agreement is being used due to the significant role NIH staff will play in assisting the investigators in the A2CPS consortium to achieve their goals.  Please see later in the FOA for information about rights and responsibilities with respect to cooperative agreements. 

    Responsiveness:  In order to provide a comprehensive molecular analysis of human biospecimens collected as a part of the A2CPS Program, all applications MUST address the following key points in order to be RESPONSIVE. Applications deemed non-responsive to this FOA by NIH staff will be withdrawn without review. ODGC applicants should plan to:

    • include at least five components in their applications: proteomics, metabolomics, lipidomics, extracellular RNA, and “other proposed assays” in addition to an administrative core and a genome variant core.
    • highlight their ability to perform reproducible analysis of blood for major types of assays:  proteomics, metabolomics, lipidomics, and extracellular RNA. We also expect the ODGCs to plan to perform human gene variant measurements using an array based format. In addition to these assay capacities, ODGC applicants may plan “other proposed assays” of potentially compelling molecular markers (e.g. cytokine levels, transcriptome/epigenome of purified cell types such as T cells or microglia from blood, microbiome, etc). NIH may support individual components from more than one U54 to ensure high quality data is generated for each category of omics assay. 
    • detail all the proposed omics assays and the total anticipated cost per assay for each sample. Cost per assay should include all direct costs necessary from sample preparation through data deposition in the DIRC (e.g. sample purification, library preparation, gene variant arrays, salaries, etc.).

    ODGC applicants should plan to: 

    • include information in their applications illustrating their past successes and how they relate to their planned A2CPS activities.
    • propose and justify at least ten potential candidate omics biomarkers (to be included as part of the final set of approximately 40 primary outcomes to be tested) that they consider as the most compelling based on the scientific literature or from their own preliminary data. The full set of study biomarkers will be finalized by the consortium during the planning year.
    • share evidence of their ability to shift effort and budget to assay the ultimate set of around 40 candidate biomarkers to be tested.
    • share how they will work with MCCs, CCC, and DIRC to establish a process, to be tracked by the DIRC, concerning the following: total biospecimen amounts to be collected, sample handling, preparation, and storage, what portions of these biological samples from the MCCs are made available to the ODGCs for analysis, how thawing and refreezing will be minimized, etc.
    • share how they will work within the consortium to establish an omics assay plan to optimize how these biological samples can be assayed to maximize useful information. Considerations will include amount of sample to be used for a given assay, number of replicates desired, standard operating procedures across ODGCs (including assay of a defined standard) to ensure reproducibility and decrease the chances of sample-to-sample variation.
    • share how they would perform qualitative and/or quantitative proteomic, metabolomic, lipidomic, and extracellular RNA assays and generate datasets of the molecules that change in response to chronic pain, with appropriate quality controls.
    • share evidence of their past and current ability to carry out large numbers of quantitative molecular assays reproducibly including information about institutional resources and staff.
    • propose to assay additional potentially compelling molecular markers (e.g. cytokine levels, transcriptome/epigenome of purified cell types such as T cells or microglia from blood, microbiome, etc). 
    • describe how they will assay patient samples for gene variants using an array-based technology.
    • work within the consortium to finalize a plan for the overall study during the planning year of award, including the development of common data elements, metadata standards, and data sharing agreements.
    • explain how they will track all raw and processed data and metadata from sample receipt to data deposition in DIRC and describe how they will provide all data and metadata to the DIRC in a standardized consortium-approved format. The goal is to ensure that all data collected can be seamlessly integrated and analyzed. Whenever possible, data formats and common data elements should be drawn from existing widely used data repositories.
    • work with the DIRC and rest of consortium to analyze omics data generated in the context of chronic pain transition or resilience and integrate those data with other patient assessments.   Participate in publications describing this work.

    Additional ODGC applicant considerations:

    • Applicants must provide a timeline and detailed quantitative annual milestones spanning the funding period. If selected for funding, applicants will work with NIH staff to develop more granular quarterly milestones for each year of funding. 
    • ODGC key personnel/consultants/team should demonstrate strong scientific expertise in the use of multiple types of omics assays to identify biosignatures from human clinical samples.
    • The effective management of the ODGCs requires a significant commitment by the PD(s)/PI(s). Applicant(s) should describe how s/he/they will manage the proposed project, who will oversee the day-to-day activities (e.g., a project manager if not the PD(s)/PI(s)), and how the management structure will support achievement of the proposed goals and milestones. Any experience coordinating large projects should be described. 
    • After award selection but prior to funding, the prospective awardee(s) for the ODGCs will be asked to submit revised budgets and research plans.
    • NIH staff do not anticipate that applications submitted to this FOA will be clinical trials given that there is no proposed intervention. 
    • Applicants should budget for the PIs and essential team members to travel domestically for four face to face meetings in year one of the program and for two annual meetings for the remainder of the funding period.

    Informational Webinar.  Prospective applicants are strongly encouraged to attend an informational webinar with NIH staff on September 6, 2018 from 2-4PM EDT. Applicants also may contact NIH scientific staff and see the FAQs (https://commonfund.nih.gov/pain/faq) for further information. 

    See Section VIII. Other Information for award authorities and regulations.

    Section II. Award Information
    Funding Instrument

    Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.  .

    Application Types Allowed

    New

    The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.

    Clinical Trial?

    Optional: Accepting applications that either propose or do not propose clinical trial(s)

    Need help determining whether you are doing a clinical trial?

    Funds Available and Anticipated Number of Awards

    Office of Strategic Coordination (Common Fund) intends to commit $0.2M in FY19 (planning year), $4M in FY20, $4M in FY21, and $2M in FY22 to fund 1-3 awards.

    Award Budget

    Application budgets are not limited but need to reflect the actual needs of the proposed project.

    Award Project Period

    Projects cannot exceed four years including the FY19 planning year

    NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

    Section III. Eligibility Information
    1. Eligible Applicants
    Eligible Organizations

    Higher Education Institutions

    • Public/State Controlled Institutions of Higher Education
    • Private Institutions of Higher Education

    The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

    o   Hispanic-serving Institutions

    o   Historically Black Colleges and Universities (HBCUs)

    o   Tribally Controlled Colleges and Universities (TCCUs)

    o   Alaska Native and Native Hawaiian Serving Institutions

    o   Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

    Nonprofits Other Than Institutions of Higher Education

    • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
    • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

    For-Profit Organizations

    • Small Businesses
    • For-Profit Organizations (Other than Small Businesses)

    Governments

    • State Governments
    • County Governments
    • City or Township Governments
    • Special District Governments
    • Indian/Native American Tribal Governments (Federally Recognized)
    • Indian/Native American Tribal Governments (Other than Federally Recognized)
    • Eligible Agencies of the Federal Government, including the NIH Intramural Program
    • U.S. Territory or Possession

    Other

    • Independent School Districts
    • Public Housing Authorities/Indian Housing Authorities
    • Native American Tribal Organizations (other than Federally recognized tribal governments)
    • Faith-based or Community-based Organizations
    • Regional Organizations
    Foreign Institutions

    Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
    Non-domestic (non-U.S.) components of U.S. Organizations are  eligible to apply.

    Foreign components, as defined in the NIH Grants Policy Statement, are  allowed.

    Required Registrations

    Applicant Organizations

    Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

    • Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
    • System for Award Management (SAM) (formerly CCR) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
    • o   NATO Commercial and Government Entity (NCAGE) Code – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM. 
    • eRA Commons - Applicants must have an active DUNS number and SAM registration in order to complete the eRA Commons registration. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
    • Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

    Program Directors/Principal Investigators (PD(s)/PI(s))

    All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons.If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

    Eligible Individuals (Program Director/Principal Investigator)

    Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

    For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

    2. Cost Sharing

    This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

    3. Additional Information on Eligibility
    Number of Applications

    Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

    The NIH will not accept duplicate or highly overlapping applications under review at the same time.  This means that the NIH will not accept:

    • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
    • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
    • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).
    Section IV. Application and Submission Information
    1. Requesting an Application Package

    A button to access the online ASSIST system is available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

    Most applicants will use NIH’s ASSIST system to prepare and submit applications through Grants.gov to NIH. Applications prepared and submitted using applicant systems capable of submitting electronic multi-project applications to Grants.gov will also be accepted.

    2. Content and Form of Application Submission

    It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

    For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.

    Letter of Intent

    Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

    By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

    • Descriptive title of proposed activity
    • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
    • Names of other key personnel
    • Participating institution(s)
    • Number and title of this funding opportunity
    • Office of Strategic Coordination (Common Fund)

    The letter of intent should be sent to:

    John Satterlee, Ph.D. 
    National Institute on Drug Abuse (NIDA)
    Telephone: 301-435-1020
    Email: satterleej@nida.nih.gov

    Page Limitations

    Available Component Types

    Research Strategy/Program Plan Page Limits

    Overall

    12 pages

    Admin Core

    6 pages

    Genetic Variant Core

    6 pages

    FOA-Specific Component: Metabolomics

    6 pages

    FOA-Specific Component: Lipidomics

    6 pages

    FOA-Specific Component: Proteomics

    6 pages

    FOA-Specific Component: Extracellular RNA

    6 pages

    FOA-Specific Component: Other Assays

    6 pages

    Additional page limits described in the SF424 Application Guide and the Table of Page Limits must be followed.

    Instructions for the Submission of Multi-Component Applications

    The following section supplements the instructions found in the SF424 (R&R) Application Guide, and should be used for preparing a multi-component application.

    The application should consist of the following components:

    • Overall Required
    • Administrative Core Required, Maximum 1
    • Genetic Variant Core Required, Maximum 1
    • Metabolomics Component Required, Maximum 1
    • Lipidomics Component Required, Maximum 1
    • Proteomics Component Required, Maximum 1
    • Extracellular RNA Component  Required, Maximum 1
    • Other Assays Component Required, Maximum 1
    Overall Component

    When preparing your application in ASSIST, use Component Type ‘Overall’.

    All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

    SF424 (R&R) Cover (Overall)

    Complete entire form.

    PHS 398 Cover Page Supplement  (Overall)

    Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.

    Research & Related Other Project Information (Overall)

    Follow standard instructions.

    Project/Performance Site Location(s) (Overall)

    Enter primary site only.

    A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.

    Research & Related Senior/Key Person Profile (Overall)

    Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this FOA) for the entire application.

    A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.

    Budget (Overall)

    The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.  

    A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.

    PHS 398 Research Plan (Overall)

    Specific Aims: The goal of the Omics Data Generation Center will be to use cutting edge technologies to perform omics analyses (e.g. metabolomic, lipidomic, proteomic, extracellular RNA) of body fluids collected by the A2CPS consortium. The omics data generated, in concert with other patient assessments, will be used to identify biosignatures predictive of susceptibility or resilience to the development of chronic pain. Applicants should describe the overall goals of the proposed ODGC for the performance period of the proposed project.

    Research Strategy: The overall research strategy should be sure to address the following items.

    • Applications that do not include a description of all five components: proteomics, metabolomics, lipidomics, extracellular RNA, and “other proposed assays” in their applications in addition to an administrative core and a genome variant core will be deemed by NIH staff to be NON-RESPONSIVE to this FOA and administratively withdrawn without review. .
    • ODGC applicants should describe their plans for the performance period and how their previous experiences have prepared them to succeed in carrying out the overall ODGC goals. This would include their ability to perform reproducible analysis of blood for major types of assays:  proteomics, metabolomics, lipidomics, and extracellular RNA. We also expect the ODGCs to perform human gene variant measurements using an array based format. In addition to these assay capacities, ODGC applicants may include “other proposed assays” of potentially compelling molecular markers (e.g. cytokine levels, transcriptome/epigenome of purified cell types such as T cells or microglia from blood, microbiome, etc). NIH may support individual components from more than one U54 to ensure high quality data is generated for each category of omics assay. 
    • Applicants should describe all the proposed omics assays and the total anticipated cost per assay for each sample. Cost per assay should include all direct costs necessary from sample preparation through data deposition in the DIRC (e.g. sample purification, library preparation, gene variant arrays, salaries, etc.).
    • Applicants should describe plans for the performance period and how their previous experiences have prepared them to succeed in carrying out the overall ODGC goals.
    • Applicants should provide a timeline and detailed quantitative annual milestones throughout the funding period.
    • Applicants should include information in their applications illustrating their past successes and how they relate to their planned A2CPS activities.
    • Applicants should propose and justify at least ten potential candidate omics biomarkers (to be included as part of the final set of approximately 40 primary outcomes to be tested) that they consider as the most compelling based on the scientific literature or from their own preliminary data. The full set of study biomarkers will be finalized by the consortium during the planning year.
    • Applicants should provide evidence of their ability to shift effort and budget to assay the ultimate set of around 40 candidate biomarkers to be tested. A panel of external experts, consortium awardees, and NIH staff, will finalize the set of selected candidate biomarkers after the consortium kick-off meeting in August/September 2019.  We expect ODGC applicants to reserve 20% of their proposed direct costs to enable their U54 to enlist additional expertise to carry out unanticipated but potentially fruitful omics assays
    • Applicants should describe how they will work with MCCs, CCC, and DIRC to establish a process, to be tracked by the DIRC, concerning the following: total biospecimen amounts to be collected, sample handling, preparation, and storage, what portions of these biological samples from the MCCs are made available to the ODGCs for analysis, how thawing and refreezing will be minimized, etc.
    • Applicants should describe how they will work within the consortium to establish an omics assay plan to optimize how these biological samples can be assayed to maximize useful information. Considerations will include amount of sample to be used for a given assay, number of replicates desired, standard operating procedures across ODGCs (including assay of a defined standard) to ensure reproducibility and decrease the chances of sample-to-sample variation.
    • Applicants should work within the consortium to finalize a plan for the overall study during the planning year of award, including the development of common data elements, metadata standards, and data sharing agreements.
    • Applicants should describe how they will track all raw and processed data and metadata from sample receipt to data deposition in DIRC and describe how they will provide all data and metadata to the DIRC in a standardized consortium-approved format. The goal is to ensure that all data collected can be seamlessly integrated and analyzed. Whenever possible, data formats and common data elements should be drawn from existing widely used data repositories.
    • Applicants should describe how they will work with the DIRC and rest of consortium to analyze omics data generated in the context of chronic pain transition or resilience and integrate those data with other patient assessments. The applicants should also describe how they will participate in publications describing this work.

    Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

    All applications should include a Data Sharing Plan.

    • A primary goal of the A2CPS program is to facilitate discoveries by the broad scientific community. Restrictive sharing practices and licensing terms for A2CPS-generated data and resources could substantially diminish their value and public benefit. Accordingly, awardees are expected to manage data, resources, protocols, and software in a way that achieves this goal.
    • Applicants should indicate their willingness to abide by all data deposition, quality control metrics, standardization, metadata requirements, data and software release, and public copyright license policies developed by the A2CPS Steering Committee and approved by NIH staff. Sharing practices that hinder, prevent or block access to or use of A2CPS program data, tools, and resources for research purposes will not be considered acceptable. The development of policies, methods, and standards for such sharing is critically important.  The NIH expects that the awardees, through the A2CPS Program Steering Committee, will develop such policies, methods, and standards in concert with the NIH.  These policies, methods, and standards must remain consistent with NIH-wide policies on data and resource sharing.
    • Specific Plan for Data Sharing. Consistent with achieving the goals of this program, the NIH expects that information such as collected data (e.g. clinical measures, brain images, patient reported outcomes, sensory testing, metabolomic, lipidomic, proteomic, etc.), technical protocols, and any other data or metadata collected under this FOA will be deposited in the DIRC.
    • Data will be made available through the A2CPS portal as appropriate via the DIRC. The A2CPS portal will serve as the central access point for information regarding data, critical tools, protocols, and reagents developed by the A2CPS program.  The A2CPS consortium will make the A2CPS data available to the scientific community using resources obtained through the NIH Data Commons (https://commonfund.nih.gov/commons) to ensure the data will be FAIR (Findable, Accessible, Interoperable, and Reusable) and accessible via cloud based data storage and computing.
    • A2CPS data will also be deposited by the DIRC (or possibly other A2CPS grantees) in appropriate public or controlled-access data repositories. Applicants should identify such repositories and describe plans for deposition. For datatypes that lack suitable public repositories, applicants should indicate their willingness to identify an appropriate alternative solution consistent with achieving the goals of the program.
    • Genomic Data Sharing Plan:  If applicants propose to generate genomic data, they must indicate their willingness to abide by the NIH Genomic Data Sharing Policy (https://gds.nih.gov/) and should indicate their agreement to it in the data sharing plan. 
    • Specific Plan for Protocol and Reagent Sharing. As one of the primary goals of this program is to advance research through development, establishment, broad dissemination and use of community resources across the research community, NIH intends that protocols and reagents generated by the A2CPS program be broadly available and distributed at minimal cost, and without undue intellectual property constraints, so that they can be as widely used as possible for research purposes by the larger scientific community.  For all applications and where otherwise applicable, the applicant should discuss plans for sharing and distribution of non-data resources that will be generated by the proposed project.  Applicants are encouraged to use Research Resource Identifiers (RRIDs).
    • The DIRC will work with all A2CPS program investigators to collect, curate, and disseminate information regarding reagents being developed by the program and to disseminate this information through the A2CPS Portal and other sources as appropriate and consistent with achieving the goals of the program.
    • Specific Plan for Sharing Software:  A software dissemination plan, with appropriate timelines, is expected in applications proposing software development.  There is no prescribed single license for software produced in this project. However, reviewers will be asked to evaluate the software sharing and dissemination plan based on its likely effectiveness. A dissemination plan guided by the following principles is thought to be the most effective:
    • ·    The software should be freely available to biomedical researchers and educators in the non-profit sector, such as institutions of education, research institutions, and government laboratories.
    • ·    The terms should also permit the dissemination and commercialization of enhanced or customized versions of the software, or incorporation of the software or pieces of it into other software packages.
    • ·    To preserve utility to the community, the software should be transferable such that another individual or team can continue development in the event that the original investigators are unwilling or unable to do so.
    • ·    The terms of software availability should include the ability of researchers outside the project and its collaborating projects to modify the source code and to share modifications with other colleagues.  An applicant should take responsibility for creating the original and subsequent "official" versions of a piece of software.
    • ·    Applicants are asked to propose a plan to manage and disseminate the improvements or customizations of their tools and resources by others.  This proposal may include a plan to incorporate the enhancements into the "official" core software, may involve the creation of an infrastructure for plug-ins, or may describe some other solution.
    • ·    Any software dissemination plans represent a commitment by the institution (and its subcontractors as applicable) to support and abide by the plan.
    • Applicants should also be familiar with the NIH statements regarding intellectual property of resources developed with Federal funds (NIH Research Tools Policy (http://grants.nih.gov/grants/intell-property_64FR72090.pdf) and other related NIH sharing policies at http://sharing.nih.gov).

    Sharing within the A2CPS

    The A2CPS program aims to maximize the benefits of sharing, while protecting the intellectual property of the data generators. Prepublication sharing of data within the consortium will allow collaboration across initiatives and further the progress of the A2CPS program towards its goals and objectives. Therefore, the A2CPS program requires that data, metadata, and resources generated from A2CPS funding be made available to other A2CPS members immediately upon being considered “shareable”. When A2CPS-generated material under embargo is shared within the A2CPS program, it will be considered confidential with the understanding that the information will not be used or disclosed by A2CPS members unless explicitly agreed upon by the originator of the data under mutually acceptable terms. That is, consortium members may not publish using material generated by other consortium members without a collaboration or other agreement, or until the material in question has been made available to the public. A2CPS investigators accessing embargoed material only available to members of the A2CPS must sign a non-disclosure form agreeing to these terms.

    Prior to funding, NIH Program Staff may negotiate modifications to the Sharing Plan with the applicant.

    Appendix:

    Limited Items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.   

    PHS Human Subjects and Clinical Trials Information (Overall)

    When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, there must be at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record within the application. The study record(s) must be included in the component(s) where the work is being done, unless the same study spans multiple components. To avoid the creation of duplicate study records, a single study record with sufficient information for all involved components must be included in the Overall component when the same study spans multiple components.

    Study Record: PHS Human Subjects and Clinical Trials Information

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Delayed Onset Study

    All instructions in the SF424 (R&R) Application Guide must be followed.

    PHS Assignment Request Form (Overall)

    All instructions in the SF424 (R&R) Application Guide must be followed. 

    Administrative Core

    When preparing your application, use Component Type ‘Admin Core.’

    All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

    SF424 (R&R) Cover (Administrative Core)

    Complete only the following fields:

    • ·    Applicant Information
    • ·    Type of Applicant (optional)
    • ·    Descriptive Title of Applicant’s Project
    • ·    Proposed Project Start/Ending Dates
    PHS 398 Cover Page Supplement (Administrative Core)

    Enter Human Embryonic Stem Cells in each relevant component.

    Research & Related Other Project Information (Administrative Core)

    Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

    Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

    Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

    Project /Performance Site Location(s) (Administrative Core)

    List all performance sites that apply to the specific component.

    Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

    Research & Related Senior/Key Person Profile (Administrative Core)

    • ·    In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
    • ·    In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
    • ·    Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
    • ·    If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   

    Budget (Administrative Core)

    Budget forms appropriate for the specific component will be included in the application package.

    Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

    PHS 398 Research Plan (Administrative Core)

    Specific Aims: Describe the overall goals of the ODGC Administrative Core for the proposed project period.

    Research Strategy: Applicants should describe how they will address some of the anticipated critical activities of the ODGC Administrative Core which include: 

    • describing how the different components of the ODGC will interact with one another and how the different components of the ODGC will interact with other funded components of A2CPS.
    • describing how the applicant's ODGC would interact with one or more additional ODGCs if more than one is funded.

    Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

    Appendix:

    Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.   

    PHS Human Subjects and Clinical Trials Information (Administrative Core)

    When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

    Study Record: PHS Human Subjects and Clinical Trials Information

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Delayed Onset Study

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Genetic Variant Core

    When preparing your application, use Component Type 'Genetic Variant Core.’

    All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

    SF424 (R&R) Cover (Genetic Variant Core)

    Complete only the following fields:

    • ·    Applicant Information
    • ·    Type of Applicant (optional)
    • ·    Descriptive Title of Applicant’s Project
    • ·    Proposed Project Start/Ending Dates

    PHS 398 Cover Page Supplement (Genetic Variant Core)

    Enter Human Embryonic Stem Cells in each relevant component.

    Research & Related Other Project Information (Genetic Variant Core)

    Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

    Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

    Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

    Project /Performance Site Location(s) (Genetic Variant Core)

    List all performance sites that apply to the specific component.

    Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

    Research & Related Senior/Key Person Profile (Genetic Variant Core)

    ASSIST will default to “Project Lead”. If you would like to use a different category, then replace “Project Lead” below with a different Category (e.g., Core Lead).

    • ·    In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
    • ·    In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
    • ·    Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
    • ·    If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   

    Budget (Genetic Variant Core)

    Budget forms appropriate for the specific component will be included in the application package.

    Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

    PHS 398 Research Plan (Genetic Variant Core)

    Specific Aims: Describe the overall goals of the ODGC Genetic Variant Core for the proposed project period

    Research Strategy:  Applicants should:

    •  describe how they will assay patient samples for gene variants using an array-based technology.
    • provide evidence of their past and current ability to carry out large numbers of genetic variant assays reproducibly including information about institutional resources and staff.

    Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

    Appendix:

    Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.   

    PHS Human Subjects and Clinical Trials Information (Genetic Variant Core)

    When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

    Study Record: PHS Human Subjects and Clinical Trials Information

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Delayed Onset Study

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Metabolomics Component

    When preparing your application, use Component Type ‘Metabolomics Core.’

    All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

    SF424 (R&R) Cover (Metabolomics Component)

    Complete only the following fields:

    • ·    Applicant Information
    • ·    Type of Applicant (optional)
    • ·    Descriptive Title of Applicant’s Project
    • ·    Proposed Project Start/Ending Dates

    PHS 398 Cover Page Supplement (Metabolomics Component)

    Enter Human Embryonic Stem Cells in each relevant component.

    Research & Related Other Project Information (Metabolomics Component)

    Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

    Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

    Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

    Project /Performance Site Location(s) (Metabolomics Component)

    List all performance sites that apply to the specific component.

    Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

    Research & Related Senior/Key Person Profile (Metabolomics Component)

    ASSIST will default to “Project Lead”. If you would like to use a different category, then replace “Project Lead” below with a different Category (e.g., Core Lead).

    • ·    In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
    • ·    In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
    • ·    Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
    • ·    If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   

    Budget (Metabolomics Component)

    Budget forms appropriate for the specific component will be included in the application package.

    Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

    PHS 398 Research Plan Metabolomics Component

    Specific Aims:   Describe the overall goals of the ODGC Metabolomics Component for the proposed project period.

    Research Strategy:   Applicants should:

    • describe how they would perform quantitative metabolomic assays on patient samples and generate datasets of the molecules that change in response to chronic pain, with appropriate quality controls.
    • provide evidence of their past and current ability to carry out large numbers of quantitative metabolomic assays reproducibly including information about institutional resources and staff.

    Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

    Appendix:

    Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.   

    PHS Human Subjects and Clinical Trials Information (Metabolomics Component)

    When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

    Study Record: PHS Human Subjects and Clinical Trials Information

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Delayed Onset Study

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Lipidomics Component

    When preparing your application, use Component Type ‘Lipidomics Core.’

    All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

    SF424 (R&R) Cover (Lipidomics Component)

    Complete only the following fields:

    • ·    Applicant Information
    • ·    Type of Applicant (optional)
    • ·    Descriptive Title of Applicant’s Project
    • ·    Proposed Project Start/Ending Dates

    PHS 398 Cover Page Supplement (Lipidomics Component)

    Enter Human Embryonic Stem Cells in each relevant component.

    Research & Related Other Project Information (Lipidomics Component)

    Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

    Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

    Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

    Project /Performance Site Location(s) (Lipidomics Component)

    List all performance sites that apply to the specific component.

    Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

    Research & Related Senior/Key Person Profile (Lipidomics Component)

    ASSIST will default to “Project Lead”. If you would like to use a different category, then replace “Project Lead” below with a different Category (e.g., Core Lead).

    • ·    In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
    • ·    In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
    • ·    Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
    • ·    If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   

    Budget (Lipidomics Component)

    Budget forms appropriate for the specific component will be included in the application package.

    Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

    PHS 398 Research Plan (Lipidomics Component)

    Specific Aims:    Describe the overall goals of the ODGC Lipidomics Component for the proposed project period.

    Research Strategy:  Applicants should:

    • describe how they would perform quantitative lipidomic assays on patient samples and generate datasets of the molecules that change in response to chronic pain, with appropriate quality controls.
    • provide evidence of their past and current ability to carry out large numbers of quantitative lipidomic assays reproducibly including information about institutional resources and staff.

    Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

    Appendix:

    Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.   

    PHS Human Subjects and Clinical Trials Information (Lipidomics Component)

    When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

    Study Record: PHS Human Subjects and Clinical Trials Information

    All instructions in the SF424 (R&R) Application Guide must be followed

    Delayed Onset Study

    All instructions in the SF424 (R&R) Application Guide must be followed

    Extracellular RNA Component

    When preparing your application, use Component Type ‘Extracellular RNA Core.’

    All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

    SF424 (R&R) Cover (Extracellular RNA Component)

    Complete only the following fields:

    • ·    Applicant Information
    • ·    Type of Applicant (optional)
    • ·    Descriptive Title of Applicant’s Project
    • ·    Proposed Project Start/Ending Dates

    PHS 398 Cover Page Supplement (Extracellular RNA Component)

    Enter Human Embryonic Stem Cells in each relevant component.

    Research & Related Other Project Information (Extracellular RNA Component)

    Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

    Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

    Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

    Project /Performance Site Location(s) (Extracellular RNA Component)

    List all performance sites that apply to the specific component.

    Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

    Research & Related Senior/Key Person Profile (Extracellular RNA Component)

    ASSIST will default to “Project Lead”. If you would like to use a different category, then replace “Project Lead” below with a different Category (e.g., Core Lead).

    • ·    In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
    • ·    In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
    • ·    Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
    • ·    If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   

    Budget (Extracellular RNA Component)

    Budget forms appropriate for the specific component will be included in the application package.

    Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

    PHS 398 Research Plan (Extracellular RNA Component)

    Specific Aims:     Describe the overall goals of the Extracellular RNA Component for the proposed project period.

    Research Strategy:    Applicants should:

    • describe how they would perform quantitative extracellular RNA assays on patient samples and generate datasets of the molecules that change in response to chronic pain, with appropriate quality controls.
    • provide evidence of their past and current ability to carry out large numbers of quantitative extracellular RNA assays reproducibly including information about institutional resources and staff.

    Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

    Appendix:

    Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.   

    PHS Human Subjects and Clinical Trials Information (Extracellular RNA Component)

    When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

    Study Record: PHS Human Subjects and Clinical Trials Information

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Delayed Onset Study

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Proteomics Component

    When preparing your application, use Component Type ‘Proteomics Core.’

    All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

    SF424 (R&R) Cover (Proteomics Component)

    Complete only the following fields:

    • ·    Applicant Information
    • ·    Type of Applicant (optional)
    • ·    Descriptive Title of Applicant’s Project
    • ·    Proposed Project Start/Ending Dates

    PHS 398 Cover Page Supplement (Proteomics Component)

    Enter Human Embryonic Stem Cells in each relevant component.

    Research & Related Other Project Information (Proteomics Component)

    Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

    Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

    Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

    Project /Performance Site Location(s) (Proteomics Component)

    List all performance sites that apply to the specific component.

    Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

    Research & Related Senior/Key Person Profile (Proteomics Component)

    ASSIST will default to “Project Lead”. If you would like to use a different category, then replace “Project Lead” below with a different Category (e.g., Core Lead).

    • ·    In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
    • ·    In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
    • ·    Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
    • ·    If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   

    Budget (Proteomics Component)

    Budget forms appropriate for the specific component will be included in the application package.

    Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

    PHS 398 Research Plan (Proteomics Component)

    Specific Aims:   Describe the overall goals of the Proteomics Component for the proposed project period.

    Research Strategy: Applicants should:

    • describe how they would perform quantitative proteomics assays on patient samples and generate datasets of the molecules that change in response to chronic pain, with appropriate quality controls.
    • provide evidence of their past and current ability to carry out large numbers of quantitative proteomics assays reproducibly including information about institutional resources and staff.

    Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

    Appendix:

    Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.   

    PHS Human Subjects and Clinical Trials Information (Proteomics Component)

    When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

    Study Record: PHS Human Subjects and Clinical Trials Information

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Delayed Onset Study

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Other Assays Component

    When preparing your application, use Component Type ‘Other Assays Core.’

    All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

    SF424 (R&R) Cover (Other Assays Component)

    Complete only the following fields:

    • ·    Applicant Information
    • ·    Type of Applicant (optional)
    • ·    Descriptive Title of Applicant’s Project
    • ·    Proposed Project Start/Ending Dates

    PHS 398 Cover Page Supplement (Other Assays Component)

    Enter Human Embryonic Stem Cells in each relevant component.

    Research & Related Other Project Information (Other Assays Component)

    Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

    Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

    Project Narrative:  Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.

    Project /Performance Site Location(s) (Other Assays Component)

    List all performance sites that apply to the specific component.

    Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.

    Research & Related Senior/Key Person Profile (Other Assays Component)

    ASSIST will default to “Project Lead”. If you would like to use a different category, then replace “Project Lead” below with a different Category (e.g., Core Lead).

    • ·    In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
    • ·    In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
    • ·    Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
    • ·    If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.   

    Budget (Other Assays Component)

    Budget forms appropriate for the specific component will be included in the application package.

    Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

    PHS 398 Research Plan (Other Assays Component)

    Specific Aims:     Describe the overall goals of the "Other Assays" Component for the proposed project period.

    Research Strategy:    Applicants should:

    • propose to assay additional potentially compelling molecular markers (e.g. cytokine levels, transcriptome/epigenome of purified cell types such as T cells or microglia from blood, microbiome, etc). 
    • justify these proposed assays using the scientific literature or their own preliminary data
    • describe how they would quantitatively perform these "other assays" on patient samples and generate datasets of the molecules that change in response to chronic pain, with appropriate quality controls.
    • provide evidence of their past and current ability to carry out large numbers of the proposed "other assays" reproducibly and quantitatively including information about institutional resources and staff.

    Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

    Appendix:

    Limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.   

    PHS Human Subjects and Clinical Trials Information (Other Assays Component)

    When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

    If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

    Study Record: PHS Human Subjects and Clinical Trials Information

    All instructions in the SF424 (R&R) Application Guide must be followed.

    Delayed Onset Study

    All instructions in the SF424 (R&R) Application Guide must be followed.

    3. Unique Entity Identifier and System for Award Management (SAM)

    See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.

    4. Submission Dates and Times

    Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

    Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time.  If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

    Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

    Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

    5. Intergovernmental Review (E.O. 12372)

    This initiative is not subject to intergovernmental review.

    6. Funding Restrictions

    All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

    Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

    7. Other Submission Requirements and Information

    Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide.  Paper applications will not be accepted.

    Applications Involving the NIH Intramural Research Program

    The requests by NIH intramural scientists will be limited to the incremental costs required for participation.   As such, these requests will not include any salary and related fringe benefits for career, career conditional or other Federal employees (civilian or uniformed service) with permanent appointments under existing position ceilings or any costs related to administrative or facilities support (equivalent to Facilities and Administrative or F&A costs).  These costs may include salary for staff to be specifically hired under a temporary appointment for the project, consultant costs, equipment, supplies, travel, and other items typically listed under Other Expenses.  Applicants should indicate the number of person-months devoted to the project, even if no funds are requested for salary and fringe benefits. 

    If selected, appropriate funding will be provided by the NIH Intramural Program.  NIH intramural scientists will participate in this program as PDs/PIs in accord with the Terms and Conditions provided in this FOA.  Intellectual property will be managed in accord with established policy of the NIH in compliance with Executive Order 10096, as amended, 45 CFR Part 7; patent rights for inventions developed in NIH facilities are NIH property unless NIH waives its rights. 

    Should an extramural application include the collaboration with an intramural scientist, no funds for the support of the intramural scientist may be requested in the application.  The intramural scientist may submit a separate request for intramural funding as described above.

    For information on how your application will be automatically assembled for review and funding consideration after submission go to: http://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.

    Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

    For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.

    Important reminders:

    All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

    The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management (SAM). Additional information may be found in the SF424 (R&R) Application Guide.

    See more tips for avoiding common errors.

    Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

    Post Submission Materials

    Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

    Section V. Application Review Information
    1. Criteria

    Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.

     A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.

    Overall Impact - Overall

    Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

    Scored Review Criteria - Overall

    Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

    Significance

    Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? How well will the proposed study transform our ability to assess the transition from acute to chronic pain? 

    In addition, for applications involving clinical trials

    Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy?  For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is this trial needed to advance scientific understanding?

    Investigator(s)

    Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI , do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? Has the investigative team previously shown the ability to participate in or lead large complex projects?  Does the team have expertise in the proposed omics analysis assays? Does the team have a history of working together?

    In addition, for applications involving clinical trials

    With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?

    Innovation

    Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? 

    In addition, for applications involving clinical trials

    Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?

    Approach

    Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed?  Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

    If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?  Has the applicant exhibited an ability to perform the proposed omics assays reproducibly, quantitatively, with the necessary throughput?  Are the plans for performing the required omics assays (metabolomic, lipidomic, proteomic, extracellular RNA, and gene variant arrays) appropriate and likely to be successful?  Are the plans for performing any additionally proposed omics assays appropriate and likely to be successful?  Which components of this U54 application are strongest and why? Which components are weakest and why?

    In addition, for applications involving clinical trials

    Does the application adequately address the following, if applicable

    Study Design

    Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?

    Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?

    Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?

    Data Management and Statistical Analysis

    Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?

    Environment

    Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? Will the environment/facilities of the institution and/or subcontracted institutions enable the completion of the proposed omics assays in the proposed time frame? 

    In addition, for applications involving clinical trials

    If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed?

    Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate?

    If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial?

    If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?

    Additional Review Criteria - Overall

    As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

     Study Timeline

    Specific to applications involving clinical trials

    Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate?

    Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?

    Protections for Human Subjects

    For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

    For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

    Inclusion of Women, Minorities, and Children 

    When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed.  For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

    Vertebrate Animals

    The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

    Biohazards

    Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

    Resubmissions

    Not Applicable

    Renewals

    Not Applicable

    Revisions

    Not Applicable

    Additional Review Considerations - Overall

    As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

    Applications from Foreign Organizations

    Not Applicable.

    Select Agent Research

    Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

    Resource Sharing Plans

    Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: 1) Data Sharing Plan; 2) Sharing Model Organisms; and 3) Genomic Data Sharing Plan .


    Authentication of Key Biological and/or Chemical Resources

    For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

    Budget and Period of Support

    Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

    2. Review and Selection Process

    Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s), convened by CSR in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

    As part of the scientific peer review, all applications:

    • May undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.
    • Will receive a written critique.

    Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

    Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:

    • Scientific and technical merit of the proposed project as determined by scientific peer review.
    • Availability of funds.
    • Relevance of the proposed project to program priorities.  
    3. Anticipated Announcement and Award Dates

    After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

    Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

    Section VI. Award Administration Information
    1. Award Notices

    If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.

    A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.

    Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

    Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website.  This includes any recent legislation and policy applicable to awards that is highlighted on this website.

    Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.  

    ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain “applicable clinical trials” on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/ 

    Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that the application as well as all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols.  Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).

    Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).  

    Prior Approval of Pilot Projects

    Awardee-selected projects that involve {clinical trials or studies involving greater than minimal risk to human subjects} require prior approval by NIH prior to initiation. 

    2. Administrative and National Policy Requirements

    All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General  and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.

    Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency.  HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

    For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see http://www.hhs.gov/ocr/civilrights/resources/laws/revisedlep.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and http://www.hhs.gov/ocr/civilrights/understanding/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at http://www.hhs.gov/ocr/office/about/rgn-hqaddresses.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.

    In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements.  FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award.  An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS.  The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 “Federal awarding agency review of risk posed by applicants.”  This provision will apply to all NIH grants and cooperative agreements except fellowships.

    Cooperative Agreement Terms and Conditions of Award

    The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75, and other HHS, PHS, and NIH grant administration policies.

    The administrative and funding instrument used for the A2CPS program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below. Awardee will retain custody of and have primary rights to the data and software developed under this award, subject to Government rights of access consistent with current DHHS, PHS, and NIH policies.

    The PD(s)/PI(s) will have the primary responsibility for:

    • Determining research approaches, designing protocols, setting project milestones, and conducting research.
    • Participating in group activities, including a Consortium-wide A2CPS Program Steering Committee and subcommittees as needed.
    • The A2CPS Consortium will meet in person four times during the planning year, at least twice a year for subsequent years, and the A2CPS Program Steering Committee will recommend the frequency of other in-person and teleconference meetings as needed. 
    • Providing reports and data in a timely fashion as agreed upon by the A2CPS Program Steering Committee.
    • Submitting all data as soon as they are collected to the A2CPS DIRC for quality control.
    • Preparing abstracts, presentations and publications and collaborating Consortium-wide in making the public and professionals aware of the program.
    • Assessing and disseminating data, protocols, and methods developed for or derived from the A2CPS program within and outside the Consortium.
    • Adhering to policies regarding data sharing and publication established by the NIH and the A2CPS Program Steering Committee.
    • Abiding by common definitions, protocols, and procedures, as chosen by majority vote of the A2CPS Program Steering Committee.
    • Submitting periodic progress reports in a standard format, as agreed upon by the A2CPS Program Steering Committee and NIH A2CPS Working Group.
    • Attending and participating in A2CPS Program Steering Committee meetings and accepting and implementing decisions by the NIH A2CPS Working Group, as appropriate.

    NIH staff will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

    The NIH A2CPS Working Group consists of NIH programmatic staff from multiple Institutes and Centers of the NIH as well as the Office of the Director.

    The NIH Project Scientist(s) will have substantial scientific and programmatic involvement during the conduct of this activity through technical assistance, advice, and coordination.  However, the role of NIH staff will be to facilitate and not to direct the activities.  The Project Scientist(s) will participate as members of the A2CPS Program Steering Committee and, the Project Scientists together will have a single vote.  The Project Scientist(s) will have the following substantial involvement:

    • Participating with the other A2CPS Program Steering Committee members in addressing issues that arise with A2CPS planning, operation, assessment, and data analysis. The Project Scientist(s) will assist and facilitate the group process and not direct it.
    • Serving as a liaison, helping to coordinate activities, including acting as a liaison to other NIH Institutes/Centers, and as an information resource for the awardees. The Project Scientist(s) will also help coordinate the efforts of the A2CPS Consortium with other groups conducting similar efforts.
    • Attending all A2CPS Program Steering Committee meetings as a voting member, assisting in developing standard operating procedures, and consistent policies for dealing with situations that require coordinated action. The Project Scientist(s) will be responsible for working with the grantees as needed to manage the logistic aspects of the A2CPS program.
    • Reporting periodically on A2CPS progress to the Common Fund A2CPS Working Group and through it to the NIH Common Fund.
    • Serving on subcommittees of the A2CPS Program Steering Committee as appropriate.
    • Assisting awardees in the development, if needed, of policies for dealing with situations that require coordinated action.
    • Providing advice in the management and technical performance of the award.
    • Assisting in promoting the availability of the data and related resources developed in the course of this program to the scientific community at large. 
    • Participating in data analyses, interpretations, and where warranted, co-authorship of the publication of results of studies conducted through the program. 
    • Other NIH A2CPS Working Group staff may assist the awardee as designated by the Program Official.

    Additionally, an agency Program Official or IC Program Director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice. The assigned Program Official may also serve as an NIH Working Group Project Scientist(s) to assist the awardee. Prior to funding an application, the Program Official will contact the applicant to discuss the proposed milestones and any changes suggested by NIH staff or the NIH review panel. The Program Official and Project Scientist will negotiate with the applicant and agree on a final set of approved milestones which will be specified in the Notice of Award. The NIH Program Official, in consultation with the Project Scientist and NIH A2CPS Working Group, will determine if the awardee has met the milestones required for each year of funding.

    NIH reserves the right to withhold funding or curtail an award in the event of:

    • Substantive changes in the project, or failure to make sufficient progress toward the work scope with which NIH concurred, or
    • Ethical or conflict of interest issues.
    • Areas of Joint Responsibility include:

    Close interaction among the participating investigators will be required, as well as significant involvement from the NIH, to manage, assess, and disseminate the A2CPS program. The awardees and the Project Scientist(s) will meet in person with the A2CPS Program Steering Committee four times during the planning year, twice a year for subsequent years, and on conference calls as needed to share information on methodologies, analytical tools, and preliminary results. PDs/PIs, key co-investigators and pre- and post-doctoral trainees, especially those who are members of under-represented minority groups or those from different but related disciplines, are eligible to attend these meetings.

    The A2CPS Program Steering Committee will serve as the main scientific body of the program.  The A2CPS Program Steering Committee will be responsible for coordinating the activities being conducted by the program and is the committee through which the NIH A2CPS Working Group formally interacts with the A2CPS investigators. The A2CPS Program Steering Committee membership will include PD(s)/PI(s) of each A2CPS award, other staff as needed (ex-officio) and the NIH Project Scientist(s). The A2CPS Program Steering Committee may add additional members, and other government staff may attend the A2CPS Program Steering Committee meetings as desired. Each project will have one vote and the NIH Program Scientist(s) together will have one vote.

    The A2CPS Program Steering Committee may establish subcommittees as needed to address particular issues, which will include representatives from the program and the NIH and possibly other experts. The A2CPS Program Steering Committee will have the overall responsibility of assessing and prioritizing the progress of the various subcommittees.

    • The A2CPS awardee agrees to work collaboratively to:
    • Provide for secure, accurate and timely data submission.
    • Participate in presenting and publishing new processes and substantive findings.
    • Assess and disseminate A2CPS data and resources
    • Participate in the governance of the A2CPS program as a member of the A2CPS Program Steering Committee.
    • Interact with other relevant NIH activities, as needed, to promote synergy and consistency among similar projects.

    External Program Consultants (EPCs):                                                                           

    • A group of EPCs will be responsible for reviewing and evaluating the progress of the entire A2CPS program. The EPCs, as appropriate and at the request of the NIH A2CPS Working Group, also will provide input to the NIH about the progress of the individual A2CPS projects in meeting their individual and Consortium goals and milestones. The EPCs will be comprised of 4-8 senior, non-federal experts who are not directly involved in the activities of the A2CPS program and who have relevant scientific expertise. NIH will appoint the EPCs and select one member as chair. The A2CPS POs, PSs, NIH A2CPS Working Group, and other NIH staff may attend the EPC meetings.
    • The EPCs will meet at least once a year, in conjunction with a meeting of the A2CPS Program Steering Committee in the DC Metro area, to allow the EPCs to interact directly with the awardees, and by phone or email, at other times as needed.
    • Annually, the EPCs will provide their individual assessments to the NIH of the progress of the A2CPS Consortium and, as necessary, will present recommendations regarding any changes to the A2CPS program. The assessments and recommendations will be provided, through the NIH A2CPS Working Group, to the Director of the Office of Strategic Coordination, NIH.

    Dispute Resolution:

    Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. The three members will be: a designee of the A2CPS Program Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special dispute resolution procedure does not alter the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.

    3. Reporting

    When multiple years are involved, awardees will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

    Progress reports should briefly describe status of pilot projects, including data and safety monitoring, and should notify NIH of serious adverse events and unanticipated problems.

    A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.

    The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later.  All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000.  See the NIH Grants Policy Statement for additional information on this reporting requirement. 

    In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period.  The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS).  This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313).  As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available.  Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75 – Award Term and Conditions for Recipient Integrity and Performance Matters.

    Section VII. Agency Contacts

    We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

    Application Submission Contacts

    eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten on-time submission, and post-submission issues)

    Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
    Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

    General Grants Information (Questions regarding application processes and NIH grant resources)
    Email: GrantsInfo@nih.gov (preferred method of contact)
    Telephone: 301-945-7573

    Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
    Contact Center Telephone: 800-518-4726
    Email: support@grants.gov

    Scientific/Research Contact(s)

    John Satterlee, Ph.D. 
    National Institute on Drug Abuse (NIDA)
    Telephone: 301-435-1020
    Email: satterleej@nida.nih.gov

    Peer Review Contact(s)

    Joseph Rudolph, Ph. D.
    Center for Scientific Review (CSR)
    Telephone: 301-408-9098
    Email:  JosephRudolph@nih.gov

    Financial/Grants Management Contact(s)

    Aida Vasquez
    National Institute on Drug Abuse (NIDA)
    Telephone: 301-480-2154  
    Email: vasquez@mail.nih.gov

    Section VIII. Other Information

    Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

    Authority and Regulations

    Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.    

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.